Drug intelligence / Profile preview

KBD141

Development stage: Preclinical
Lead developer: Baiyu Pharmaceutical
Modality: Small Molecules

Overview

KBD141 is a small molecule drug candidate currently in development by Chengdu Baiyu Jingelai Pharmaceutical, a subsidiary of Chengdu Baiyu Pharmaceutical. The asset is specifically targeted toward the treatment of skin inflammation. While the exact biological target and mechanism of action remain undisclosed by the developer, the drug represents part of the company's research and development pipeline in the dermatology therapeutic area. As of current pipeline information, the drug is in the early stages of development for inflammatory skin conditions.

Targets

THRB (Thyroid hormone receptor beta)THRA (Thyroid hormone receptor alpha)

Beyond the preview

Go deeper on KBD141.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KBD141.

Explore the full profile